Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (4): 716-722. doi: 10.19723/j.issn.1671-167X.2019.04.021

Previous Articles     Next Articles

Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms

Hong-lin ZHU,Qian DU,Wei-lin CHEN,Xiao-xia ZUO,Quan-zhen LI,Si-jia LIU()   

  1. Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha 410008, China
  • Received:2019-01-11 Online:2019-08-18 Published:2019-09-03
  • Contact: Si-jia LIU E-mail:celialiu@csu.edu.cn
  • Supported by:
    Supported by the National Natural Science Foundation of China(81671622);Supported by the National Natural Science Foundation of China(81771765);Hunan Provincial Natural Science Fundation(2018JJ3823)

Abstract:

Objective: To analyze the expression profile of serum cytokines in patients with systemic sclerosis (SSc) and explore its possible regulatory mechanisms.Methods: Serum and DNA of peripheral blood mononuclear cells were collected from 30 SSc patients and 80 normal controls (NCs). According to the presence or absence of interstitial lung disease (ILD) in SSc, the patients were divided into SSc with ILD group and SSc without ILD group. According to the degree of skin involvement, the patients were divided into diffuse systemic scleroderma (dcSSc) group and limited systemic scleroderma (lcSSc) group. According to the presence of anti-topoisomerase-1 antibody (anti-Scl-70 antibody) in the serum of patients with SSc, they were divided into SSc Scl-70 (+) group and SSc Scl-70 (-) group. 27 cytokines in serum were detected by Luminex MAGPIX detection system and Bio-Plex Pro Human Cytokine 27-plex Assay kit: interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12P70, IL-13, IL-15, IL-17, basic fiber growth factor (BASIC FGF), eotaxin, granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-γ (IFN-γ), interferon-gamma induced protein 10(IP-10), monocyte chemotactic protein 1(MCP-1), macrophage inflammatory protein-1α(MIP-1α), macrophage inflammatory protein 1β(MIP-1β), platelet-derived growth factor BB (PDGF-BB), regulated on activation in normal T-cell expressed and secreted (RANTES), tumor necrosis factor-α (TNF-α), and vascular endothelial growth factor(VEGF). Methylation sites were detected by Illumina 450K methylation chip.Results: Compared with NCs group, the expression of 12 cytokines (BASIC FGF, eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-6, IP-10, MCP-1, TNF-α and RANTES) in the SSc group significantly increased (P<0.05), IL-5 was decreased expression in the SSc group (P<0.05), there was no signi-ficant difference in the expressions of the other 14 cytokines. Compared with lcSSc group, 9 cytokines (eotaxin, IL-5, MCP-1, IL-2, RANTES, IL17A, IL-8, MIP-1β and PDGF-BB) increased in dcSSc group, but there was no significant difference. Compared with SSc without ILD group, IL-15 increased in SSC with ILD group [18.2(172.97) ng/L vs. 2.03(0.05) ng/L, P<0.05]. Compared with SSc Scl-70 (-) group, the expression of IP-10 decreased in SSc Scl-70 (+) group [1 030 (2 196.6) ng/L vs. 1 878 (2 964) ng/L, P<0.05]. The correlation analysis of serum cytokines with erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) showed that IL-6 was positively correlated with ESR (r =0.04, P= 0.017), MCP-1 (r= 0.49, P= 0.043) and MIP-1β (r= 0.41, P= 0.007) positively correlated with CRP. By analyzing the changes of methylation sites of cytokines, it was found that cg17744604 in IL-10 TSS1500 region, cg06111286 in IL-12P70 TSS200 region, cg07935264 in IL-1 β TSS200 region, cg01467417 in IL-1ra TSS1500 region, cg03989987 in IL-1ra 5'UTR region and cg21099624 in VEGF TSS200 region were all hypomethylated.Conclusion: There were different cytokines expression profiles in the serum of SSc patients, and the altered cytokines were correlected with the degree of skin damage and pulmonary fibrosis. Many cytokines were regulated by methylation.

Key words: Systemic sclerosis, Cytokine, Genome-wide methylation

CLC Number: 

  • R593.25

Table 1

Altered serum cytokine expression profiles in SSc, dsSSc and lcSSc groups/(ng/L), Median (IQR)"

Cytokine NCs (n=80) SSc (n=30) P value
(NC vs. SSc)
lcSSc (n=10) dcSSc (n=20) P value
(lcSSc vs. dcSSc)
BASIC FGF 64.27 (42.37) 88.51 (46.58) 0.002 94.07 (49.47) 86.70 (48.08) >0.05
Eotaxin 145.90 (89.30) 178.80 (155.70) 0.039 139.40 (127.30) 188.60 (156.60) >0.05
G-CSF 75.87 (58.45) 113.90 (104.84) <0.001 122.40 (149.89) 108.00 (82.50) >0.05
GM-CSF 30.75 (57.51) 53.17 (124.65) 0.039 106.50 (96.09) 42.76 (134.16) >0.05
IFN-γ 65.50 (75.52) 198.60 (149.60) <0.001 259.20 (224.60) 194.90 (116.90) >0.05
IL-5 8.76 (23.13) 3.28 (4.27) 0.001 3.28 (10.23) 4.63 (4.57) >0.05
IL-1β 1.62 (27.08) 6.58 (6.64) <0.001 7.69 (5.82) 5.46 (10.36) >0.05
IL-1ra 143.70 (177.36) 481.60 (613.10) <0.001 541.40 (514.60) 359.50 (399.10) >0.05
IL-6 21.58 (32.72) 35.92 (31.39) 0.002 34.49 (40.10) 33.86 (21.01) >0.05
IP-10 766.00 (523.40) 1 307.00 (2 506.40) 0.002 2 096.00 (2 885.00) 1 094.00 (2 081.60) >0.05
MCP-1 118.30 (73.10) 229.60 (319.40) <0.001 180.30 (284.18) 261.00 (548.40) >0.05
TNF-α 43.17 (33.35) 62.64 (43.74) <0.001 63.43 (61.72) 55.81 (39.60) >0.05
RANTES 23 404.00 (27 482.00) 52 632.00 (75 694.00) 0.019 42 802.00 (80 383.00) 71 752.00 (75 270.00) >0.05
IL-2 37.29 (54.92) 5.04 (30.77) 0.053 4.48 (36.44) 5.04 (29.21) >0.05
VEGF 153.10 (139.00) 204.00 (278.90) 0.052 304.80 (338.20) 150.30 (285.10) >0.05
IL-10 19.43 (30.78) 19.84 (15.76) >0.05 23.91 (36.54) 18.92 (12.44) >0.05
IL-15 13.88 (46.35) 2.03 (20.51) >0.05 2.03 (7.33) 2.03 (42.40) >0.05
IL-17A 92.95 (108.01) 127.20 (64.19) >0.05 119.00 (76.45) 143.50 (97.83) >0.05
MIP-1α 7.46 (23.51) 6.76 (4.90) >0.05 7.56 (5.43) 6.66 (4.48) >0.05
IL-4 7.30 (17.02) 5.92 (3.51) >0.05 6.39 (6.85) 5.98 (4.23) >0.05
IL-7 23.91 (19.28) 19.26 (15.27) >0.05 20.67 (29.32) 19.79 (13.86) >0.05
IL-8 48.05 (55.05) 41.05 (32.61) >0.05 36.59 (54.53) 42.06 (31.75) >0.05
IL-9 35.19 (71.11) 36.04 (32.79) >0.05 43.78 (52.64) 35.57 (26.95) >0.05
IL-13 21.49 (23.94) 17.51 (43.08) >0.05 21.25 (88.46) 16.15 (15.30) >0.05
MIP-1β 317.80 (280.30) 290.60 (260.70) >0.05 254.30 (273.70) 324.60 (231.60) >0.05
IL-12P70 45.26 (25.25) 45.89 (45.64) >0.05 57.69 (43.41) 41.08 (43.54) >0.05
PDGF-BB 4 623.00 (2 680.00) 4 701.00 (2 770.00) >0.05 3 911.00 (2 521.00) 5 598.00 (3 036.00) >0.05

Table 2

Altered serum cytokine expression profiles in SSc ILD(+)、SSc Scl-70(+) groups/(ng/L), Median (IQR)"

Cytokine SSc ILD(-)
(n=15)
SSc ILD(+)
(n=15)
P value
[ILD(-) vs.
ILD(+)]
SSc Scl-70(-)
(n=10)
SSc Scl-70(+)
(n=20)
P value
[Scl-70(-) vs.
Scl-70(+)]
BASIC FGF 88.51 (42.70) 99.08 (51.46) >0.05 77.49 (40.47) 89.70 (50.58) >0.05
Eotaxin 172.10 (140.60) 185.40 (195.20) >0.05 158.40 (402.00) 188.60 (179.00) >0.05
G-CSF 122.40 (128.54) 112.00 (97.04) >0.05 105.40 (230.59) 115.90 (89.78) >0.05
GM-CSF 52.97 (86.94) 121.60 (136.55) >0.05 49.65 (143.35) 53.17 (122.49) >0.05
IFN-γ 205.90 (131.00) 184.00 (188.80) >0.05 238.10 (943.10) 187.70 (114.80) >0.05
IL-12P70 36.59 (44.73) 47.48 (34.56) >0.05 50.77 (186.11) 45.89 (46.69) >0.05
IL-1β 6.30 (5.34) 9.23 (23.73) >0.05 6.58 (40.19) 7.05 (6.57) >0.05
IL-1ra 460.40 (508.50) 502.90 (792.10) >0.05 500.90 (6421.90) 456.30 (524.80) >0.05
IL-6 35.74 (16.38) 36.27 (119.28) >0.05 27.34 (170.27) 36.36 (33.49) >0.05
IP-10 1 418.00 (2 969.90) 1 182.00 (2 306.60) >0.05 1 878.00 (2 964.00) 1 030.00 (2 196.60) 0.039
MCP-1 180.40 (179.90) 323.10 (571.20) >0.05 175.00 (216.12) 296.90 (499.10) >0.05
TNF-α 71.00 (39.17) 52.80 (118.41) >0.05 51.18 (315.81) 69.48 (41.94) >0.05
VEGF 193.70 (210.20) 298.10 (388.80) >0.05 275.20 (428.40) 176.30 (232.30) >0.05
IL-13 24.73 (83.62) 15.12 (36.66) >0.05 18.94 (76.56) 17.51 (55.58) >0.05
IL-7 18.19 (18.71) 19.61 (12.01) >0.05 18.02 (57.74) 21.20 (15.01) >0.05
RANTES 45 504.00 (74 609.00) 59 759.00 (77 217.00) >0.05 78 450.00 (76 739.00) 38 953.00 (75 650.00) >0.05
IL-10 18.28 (11.81) 23.40 (13.45) >0.05 14.85 (156.50) 21.64 (14.77) >0.05
IL-15 2.03 (0.05) 18.20 (172.97) 0.024 2.03 (63.31) 2.03 (25.19) >0.05
IL-17A 122.30 (66.79) 145.20 (112.53) >0.05 123.90 (43.10) 134.50 (73.82) >0.05
IL-2 2.84 (16.57) 5.95 (34.50) >0.05 4.36 (180.43) 5.08 (29.21) >0.05
MIP-1α 6.76 (3.18) 6.46 (20.36) >0.05 6.51 (6.51) 7.74 (4.39) >0.05
IL-4 6.23 (4.63) 5.72 (3.04) >0.05 6.05 (10.81) 5.85 (3.51) >0.05
IL-5 3.21 (3.90) 3.34 (4.84) >0.05 4.09 (10.88) 3.21 (3.21) >0.05
IL-8 37.45 (21.89) 49.71 (47.20) >0.05 40.31 (58.24) 41.05 (28.72) >0.05
IL-9 36.22 (35.10) 35.86 (30.29) >0.05 33.01 (30.67) 38.56 (29.77) >0.05
MIP-1β 260.70 (285.40) 310.60 (420.10) >0.05 312.30 (293.10) 290.60 (243.80) >0.05
PDGF-BB 4 359.00 (3 072.00) 5 043.00 (3 128.00) >0.05 4 827.00 (3 340.00) 4 701.00 (2 958.00) >0.05

Table 3

The correlation of serum cytokine expression profile with ESR, CRP in SSc"

Cytokine ESR CRP
r P r P
BASIC FGF -0.09 0.009 0.12 >0.05
Eotaxin -0.12 0.013 0.15 >0.05
G-CSF -0.11 0.004 0.19 >0.05
GM-CSF -0.04 0.012 0.05 >0.05
IFN-γ -0.07 0.010 0.10 >0.05
IL-10 -0.09 0.002 0.25 >0.05
IL-12P70 -0.19 <0.001 0.16 >0.05
IL-15 0.09 >0.05 0.08 >0.05
IL-17A 0.05 >0.05 0.14 >0.05
IL-1β -0.06 0.008 0.23 >0.05
IL-1ra -0.02 0.011 0.10 >0.05
IL-2 -0.31 <0.001 0.07 >0.05
IL-6 0.04 0.017 0.30 >0.05
IP-10 -0.02 >0.05 0.09 >0.05
MCP-1 0.09 >0.05 0.49 0.043
MIP-1α -0.05 >0.05 0.38 >0.05
TNF-α -0.06 0.011 0.16 >0.05
VEGF -0.13 0.024 0.17 >0.05
IL-13 -0.35 <0.001 -0.07 0.050
IL-4 -0.2 0.005 0.04 >0.05
IL-5 -0.07 0.034 0.06 >0.05
IL-7 -0.04 0.006 0.17 >0.05
IL-8 0.09 >0.05 0.32 >0.05
IL-9 -0.21 0.001 0.30 >0.05
MIP-1β -0.02 >0.05 0.41 0.007
PDGF-BB -0.04 >0.05 -0.01 0.042
RANTES 0.17 >0.05 0.02 >0.05

Table 4

Altered methylation expression of cytokines"

Cytokine Gene Methylation sites NCs β (Mean) SSc β (Mean) Δβ P value Gene locus Chromosomal location
IL-10 IL10 cg17744604 0.403 0.297 -0.106 <0.001 TSS1500 1
IL-12P70 IL12B cg06111286 0.316 0.250 -0.066 0.001 TSS200 5
IL-1β IL1B cg07935264 0.195 0.150 -0.045 <0.001 TSS200 2
IL-1ra IL1RN cg01467417 0.127 0.108 -0.019 0.014 TSS1500 2
IL-1ra IL1RN cg03989987 0.301 0.238 -0.063 0.006 5'UTR 2
VEGF VEGFA cg21099624 0.097 0.089 -0.008 0.011 TSS200 6
[1] Denton CP, Khanna D . Systemic sclerosis[J]. Lancet, 2017,390(10103):1685-1699.
[2] Allanore Y, Simms R, Distler O , et al. Systemic sclerosis[J]. Nat Rev Dis Primers, 2015: 15002.( 2015-04-23)[2018-12-01]. .
[3] LeRoy EC, Black C, Fleischmajer R , et al. Scleroderma (syste-mic sclerosis): classification, subsets and pathogenesis[J]. J Rheumatol, 1988,15(2):202-205.
[4] Bhattacharyya S, Wei J, Varga J . Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities[J]. Nat Rev Rheumatol, 2011,8(1):42-54.
[5] Raja J, Denton CP . Cytokines in the immunopathology of systemic sclerosis[J]. Semin Immunopathol, 2015,37(5):543-557.
[6] Dantas AT, Almeida AR, Sampaio M , et al. Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations[J]. Immunol Lett, 2018,198:12-16.
[7] Zhu H, Zhu C, Mi W , et al. Integration of genome-wide DNA methylation and transcription uncovered aberrant methylation-regulated genes and pathways in the peripheral blood mononuclear cells of systemic sclerosis[J]. Int J Rheumatol, 2018:7342472.(2018-09-02)[2018-12-11]. .
[8] Masi AT . Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee[J]. Arthritis Rheum, 1980,23(5):581-590.
[9] Burska A, Boissinot M , Ponchel F. Cytokines as biomarkers in rheumatoid arthritis[J]. Mediators Inflamm, 2014: 545493.( 2014-03-09)[2018-12-22]..
[10] Needleman BW, Wigley FM, Stair RW . Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma[J]. Arthritis Rheum, 1992,35(1):67-72.
[11] Hasegawa M, Fujimoto M, Kikuchi K , et al. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis[J]. J Rheumatol, 1997,24(2):328-332.
[12] Hasegawa M, Fujimoto M, Matsushita T , et al. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis[J]. Clin Rheumatol, 2011,30(2):231-237.
[13] Wuttge DM, Wildt M, Geborek P , et al. Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease[J]. Arthritis Res Ther, 2007,9(5):R85.
[14] Takada T, Ohashi K, Hayashi M , et al. Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody[J]. Respir Med, 2018,141:7-13.
[15] Antonelli A, Ferri C, Fallahi P , et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis: a longitudinal study[J]. Rheumatology (Oxford), 2008,47(1):45-49.
[16] Goser S, Ottl R, Brodner A , et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy[J]. Circulation, 2005,112(22):3400-3407.
[17] Feinberg AP . The key role of epigenetics in human disease prevention and mitigation[J]. N Engl J Med, 2018,378(14):1323-1334.
[18] McInnes IB, Buckley CD, Isaacs JD . Cytokines in rheumatoid arthritis-shaping the immunological landscape[J]. Nat Rev Rheumatol, 2016,12(1):63-68.
[19] van der Heijde D, Cheng-Chung Wei J, Dougados M , et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial[J]. Lancet, 2018,392(10163):2441-2451.
[20] Chen Z, Bozec A, Ramming A , et al. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis[J]. Nat Rev Rheumatol, 2019,15(1):9-17.
[1] Duo YANG,Xin-na ZHOU,Shuo WANG,Xiao-li WANG,Yan-hua YUAN,Hua-bin YANG,Hui-zhen GENG,Bing PENG,Zi-bo LI,Bin LI,Jun REN. Assessment of lymphocytic function in vitro stimulated by specific tumor polypeptide combined with dendritic cells [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1094-1098.
[2] MA Xiang-bo,ZHANG Xue-wu,JIA Ru-lin,GAO Ying,LIU Hong-jiang,LIU Yu-fang,LI Ying-ni. Application of lymphocytes test in peripheral blood of patients with systemic sclerosis during the treatment [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 721-727.
[3] Jing ZHAO,Feng SUN,Yun LI,Xiao-zhen ZHAO,Dan XU,Ying-ni LI,Yu-hui LI,Xiao-lin SUN. Significance of anti-tubulin-α-1C autoantibody in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1009-1013.
[4] Jia-xing LIU,Gui-ping HU,Lin ZHAO,Yong-ming ZHANG,Li WANG,Guang JIA,Rui-xiang LIU,Hui-min FENG,Hua-dong XU. Early effects of low-level long-term occupational chromate exposure on workers’ health [J]. Journal of Peking University(Health Sciences), 2019, 51(2): 307-314.
[5] DOU Jing-li,BAI Li,PANG Chun-yan,ZHANG Wen-lan,ZHANG Wei,WANG Yong-fu. Therapeutic effect of adipose tissue-derived stem cells on bleomycin-induced mice of scleroderma [J]. Journal of Peking University(Health Sciences), 2016, 48(6): 970-976.
[6] AN Le-mei, LI Juan, JI Lan-lan, LI Guang-tao, ZHANG Zhuo-li. Detection of peripheral follicular helper T cells in rheumatoid arthritis [J]. Journal of Peking University(Health Sciences), 2016, 48(6): 951-957.
[7] WANG Zhi-hua, ZHANG Wei, ZHANG Yan-qing, PANG Chun-yan,WANG Yong-fu. Effect of CD40 siRNA on inflammatory response of MRL/Lpr mice [J]. Journal of Peking University(Health Sciences), 2016, 48(5): 771-776.
[8] LI Hao, ZHANG You-Yi.
Roles of proinflammatory cytokines in cardiac remodeling induced by sympathetic nervous system /catecholamine
[J]. Journal of Peking University(Health Sciences), 2014, 46(6): 1001-1004.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2009, 41(6): 682 -686 .
[6] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .